Nicolin Bloch

Title: Nicolin Bloch: Innovator in Cancer Treatment

Introduction

Nicolin Bloch is a prominent inventor based in Ossining, NY (US), known for his significant contributions to the field of cancer treatment. With a total of 2 patents, he has made strides in developing innovative therapies aimed at inhibiting cancer and tumor growth.

Latest Patents

One of Nicolin's latest patents focuses on IL-2 variants with reduced binding to the IL-2 receptor alpha. This disclosure relates to methods of using these IL-2 variants for treating or inhibiting cancer or tumors. The IL-2 variants are designed to have a reduced ability to bind to or activate IL-2Rα while retaining the ability to bind to or activate IL-2Rβ and/or IL-2Rγ. Additionally, these variants may exhibit decreased Treg activity while maintaining the capacity to activate NK cells and T effector cells.

Career Highlights

Nicolin Bloch is currently associated with Regeneron Pharmaceuticals, Inc., where he continues to work on groundbreaking research in immunotherapy. His expertise in the field has positioned him as a valuable asset in the development of novel cancer treatments.

Collaborations

Nicolin collaborates with talented individuals such as Jiaxi Wu and Tong Zhang, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Nicolin Bloch's work in developing IL-2 variants represents a significant advancement in cancer treatment, showcasing his dedication to improving patient outcomes through innovative therapies. His contributions to the field are noteworthy and continue to inspire future research.